Indication

Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

• About Ventavis

• About the I-neb AAD
  System

•      PAH Pathways

•      Specialty Pharmacy

• Resources

• Prescribing Information

• For Patients and
  Caregivers

Services for Your Patients

All patients prescribed Ventavis^® (iloprost) are offered a range of support services to help them be successful with their therapy. From filling a prescription to reimbursement assistance, from I-neb AAD System training to long-term education and support, Ventavis services provide your patients with resources and care. This entire support structure has one purpose only: to help your patients get the most out of Ventavis therapy.

If you are considering placing your patient on Ventavis, the PAH Pathways™ program is designed to facilitate the initiation of Ventavis therapy. For more information on the PAH Pathways program, please call 1-866-228-3546.

Read more about Ventavis Services for Your Patients:

• PAH Pathways
• Specialty Pharmacy
• Resources

IMPORTANT SAFETY INFORMATION

Hypotension leading to syncope has been observed; Ventavis should therefore not be initiated in patients with systolic blood pressure less than 85 mmHG. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension. Ventavis inhalation may cause brochospasm and patients with a history of hyperreactive airway disease may be more sensitive. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Ventavis has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants.

Please see full Prescribing Information